Lilly to pay $8bn for Loxo Oncology as cancer M&A soars

By Mike Turner
07 Jan 2019

Eli Lilly, the US pharmaceuticals company, has agreed to buy Loxo Oncology for around $8bn, as big ticket consolidation in the drug sector continues apace.

Eli Lilly has agreed to pay $235 a share in cash for Loxo, a biopharmaceuticals company that makes medicines for certain types of cancer. The price is a 68% premium to Loxo's closing price on January 4.

Deutsche Bank is advising Eli Lilly, while Goldman Sachs is advising Loxo. 

The ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.